Sarkar FH - Search Results

1

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.

El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. El-Rayes BF, et al. Among authors: sarkar fh. Invest New Drugs. 2011 Aug;29(4):694-9. doi: 10.1007/s10637-010-9386-6. Epub 2010 Jan 27. Invest New Drugs. 2011. PMID: 20107864 Clinical Trial.

2

Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.

Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Merati K, et al. Am J Clin Oncol. 2001 Oct;24(5):447-52. doi: 10.1097/00000421-200110000-00007. Am J Clin Oncol. 2001. PMID: 11586094

3

Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis.

Glazyrin AL, Chinni S, Alhasan S, Adsay VN, Vaitkevicius VK, Sarkar FH. Glazyrin AL, et al. Among authors: sarkar fh. Int J Oncol. 2002 Jan;20(1):201-5. Int J Oncol. 2002. PMID: 11743665

4

Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians.

Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius VK, Dugan MC, Adsay NV. Pernick NL, et al. Among authors: sarkar fh. Pancreas. 2003 Jan;26(1):28-32. doi: 10.1097/00006676-200301000-00006. Pancreas. 2003. PMID: 12499914

5

Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.

Ali S, Aranha O, Li Y, Pettit GR, Sarkar FH, Philip PA. Ali S, et al. Among authors: sarkar fh. Cancer Chemother Pharmacol. 2003 Sep;52(3):235-46. doi: 10.1007/s00280-003-0628-6. Epub 2003 Jun 14. Cancer Chemother Pharmacol. 2003. PMID: 12811511

6

Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues.

Li Y, Ali S, Philip PA, Sarkar FH. Li Y, et al. Among authors: sarkar fh. Cancer Detect Prev. 2003;27(5):405-11. doi: 10.1016/s0361-090x(03)00105-3. Cancer Detect Prev. 2003. PMID: 14585328

7

Soy isoflavones and cancer prevention.

Sarkar FH, Li Y. Sarkar FH, et al. Cancer Invest. 2003;21(5):744-57. doi: 10.1081/cnv-120023773. Cancer Invest. 2003. PMID: 14628433 Review.

8

Soy isoflavones in the treatment of prostate cancer.

Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Hussain M, et al. Among authors: sarkar fh. Nutr Cancer. 2003;47(2):111-7. doi: 10.1207/s15327914nc4702_1. Nutr Cancer. 2003. PMID: 15087261

9

Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line.

Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH. Li Y, et al. Among authors: sarkar fh. Pancreas. 2004 May;28(4):e90-5. doi: 10.1097/00006676-200405000-00020. Pancreas. 2004. PMID: 15097869

10

Cytochrome p450 and glutathione transferase expression in squamous cell cancer.

Ali S, El-Rayes BF, Heilbrun LK, Sarkar FH, Ensley JF, Kucuk O, Philip PA. Ali S, et al. Among authors: sarkar fh. Clin Cancer Res. 2004 Jul 1;10(13):4412-6. doi: 10.1158/1078-0432.CCR-04-0145. Clin Cancer Res. 2004. PMID: 15240530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

552 results

Search Page

Filters